MDMA for Eating Disorders

1 paper and 1 clinical trial exploring mdma as a treatment for eating disorders.

Compoundempathogen

MDMA

MDMA is a synthetic empathogen that enhances monoamine release, producing prosocial and anxiolytic effects without frank hallucinosis. Two Phase III trials demonstrated significant PTSD symptom reductions, though FDA review raised concerns about blinding, durability, and safety characterisation.

Full MDMA profile

Indication16 million people worldwide.

Eating Disorders

Eating disorders, including anorexia nervosa and bulimia nervosa, affect approximately 16 million individuals globally. The exploration of psychedelics, such as psilocybin and MDMA, as potential treatments for these conditions is a burgeoning field of research, showing promise in alleviating symptoms and improving quality of life.

Full Eating Disorders profile

Academic Research

1 paper

Open Accessindividual

MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD

This trial (n=90) used the Eating Attitudes Test (EAT-26) to assess the impact MDMA-assisted therapy has on symptoms of eating disorders (ED) in participants with PTSD. There was a significant reduction in total EAT-26 scores in the total group of PTSD participants following MDMA-AT versus placebo (p = .03). Overall, MDMA-AT significantly reduced ED symptoms compared to therapy with placebo among participants with severe PTSD.

Published: May 1, 2022
Journal: Journal of Psychiatric Research
Authors: Brewerton, T. D., Doblin, R., Emerson, A., Lafrance, A., Mithoefer, M. C., Wang, J. B., Yazar-Klosinski, B.

Clinical Trials

1 trial

WithdrawnPhase II

A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders

Open-label Phase II multi-site study (n=18) assessing three sessions of MDMA-assisted psychotherapy (80–120 mg oral MDMA with supplemental half-doses) with preparatory and integrative therapy and caregiver involvement in female participants with AN‑R or BED.

Started: June 1, 2023
Type: interventional
Blinding: none
Randomized: No
Registry ID: NCT04454684

Explore further

Search all MDMA papers Search all Eating Disorders trials Full MDMA profile Full Eating Disorders profile